archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Archived ASX Releases
    UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases Full Year Results for 2008 Full Year Results for 2008 Melbourne Australia 13 08 2008 CSL Limited today announced its operating results for the full year ended 30 June 2008 Download the full release Full Year Results for 2008 For

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1218118041988/prdetail.htm (2014-01-05)
    Open archived version from archive


  • Archived ASX Releases
    US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases CSL Half Year Results Announcement for 2007 08 CSL Half Year Results Announcement for 2007 08 Melbourne Australia 20 02 2008 CSL Limited today announced its first half result for period ended 31 December 2007 Download this release CSL Half Year Results Announcement for

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1199979298939/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    Limited Warns Shareholders of Unsolicited Share Offers Melbourne Australia 10 02 2008 CSL Limited has become aware of unsolicited offers to shareholders to purchase their shares for a price which significantly undervalues their holding CSL has advised shareholders on receipt of such an offer that they check it carefully CSL urges shareholders to speak with their broker or financial advisor for advice if they are uncertain as to what to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1199979263555/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited announced today that it is partnering with the world’s largest health research agency, the US National Institutes of Health (NIH), to study a potential new treatment for the prevention of congenital CMV infection, one of the most common known c
    blood and mucus and is predominantly carried by healthy infants preschoolers and children who contract the virus from their peers Approximately one to two percent of pregnant women are infected with CMV for the first time during their pregnancy and one in three will pass the CMV infection on to their developing unborn child The risk of CMV infection is reduced by hand washing and general hygiene In Australia CMV is one of the leading causes of disabilities in infants including deafness blindness cerebral palsy mental and physical disabilities seizures and even death The symptoms of CMV may not be immediately apparent at birth and even well beyond There is currently no proven therapeutic prevention for congenital CMV Starting this month the NIH will initiate a large multi site clinical trial in the US involving more than 150 000 women to test whether CMV immunoglobulin antibodies collected from human plasma is an effective preventative of mother to baby transmission of CMV CSL is donating product made at its Swiss plant to the NIH for use in this trial as part of its commitment to addressing significant public health issues through collaborative research Professor Bill Rawlinson Senior Medical Virologist at UNSW and CMV expert welcomed the study Robust information about prevention of congenital CMV is needed now One to two babies are born every day with profound medical problems from congenital CMV that might be able to be prevented The commitment by the NIH and CSL to conduct a large study like this will hopefully provide more definitive answers and options for the prevention of mother to baby transmission of CMV Dr Andrew Cuthbertson Chief Scientific Officer of CSL added This is a very large complex and long term trial that requires the resources of a research agency like the NIH

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927806982/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL wins equal opportunity award for onsite childcare centre
    its work in establishing an innovative onsite childcare centre at its corporate headquarters in Melbourne The company today received the Minister s Award for Outstanding Equal Employment Opportunity Initiative for its recently opened Thinking Kids Children s Centre a purpose built architecturally designed facility offering 114 places for children aged up to six years located at its Parkville Melbourne site The annual award presented by Federal Minister for the Status of Women Kate Ellis at a luncheon in Sydney recognises organisations that implement outstanding strategic initiatives aimed at effectively addressing issues related to equal employment opportunity for women The centre which opened on September 19 provides priority access to CSL employees with places also available to the wider community CSL Biotherapies Executive Vice President Dr Jeff Davies accepting the award on behalf of CSL said women represented 51 of the CSL Australian workforce and brought enormous value to the business We know that to continue to attract and retain talented women we must provide a supportive and inclusive workplace and minimise the barriers to career progression Dr Davies said CSL s work to establish the centre started over five years ago when internal research indicated that an onsite childcare facility would strengthen maternity leave retention and enhance the company s offering to potential new employees Equal Opportunity in the Workplace Agency Director EOWA Helen Conway today congratulated CSL for providing the 4 8 million childcare centre This facility is a boon to employees who may have had to postpone their careers once they became caregivers due to a lack of access to adequate childcare CSL and its people will continue to gain from this important investment said Ms Conway The facility has proven extremely popular among CSL s workforce in the months since its opening Early Childhood Management Services which

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927606177/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited today announced CSL announces A$900m share buy-back
    of up to A 900 million of CSL shares Speaking at CSL s annual general meeting in Melbourne today CSL Chairman Elizabeth Alexander said the Board was pleased to be able to continue to return capital to shareholders Through these buybacks our shareholders benefit from improved investment return ratios such as earnings per share and return on equity said Ms Alexander At yesterday s closing price of A 30 21 a A 900 million buy back represents approximately 30 million CSL shares or around 6 of CSL s issued share capital It is CSL s fifth share buy back with the Company returning almost 20 of its shares to shareholders since 2005 Ms Alexander also told shareholders today that the Company was well progressed in achieving the capital management initiatives foreshadowed earlier this year I am pleased to announce that CSL is now close to finalising negotiations with its banks for new lines of credit for up to the equivalent of A 750 million CSL has also raised US 750 million through a US private placement subject to final documentation and closing The placement was well received by investors and was significantly oversubscribed The new credit facilities and debt placement will significantly lengthen CSL s debt profile at very attractive long term interest rates and will enable CSL to move towards its objective of maintaining a leverage ratio Net Debt to EBIDTA within the range of 0 7 to 1 2 This is an excellent outcome given the volatility of the financial markets and is a welcome endorsement of the strength of the Company s balance sheet and operating position said CSL s Chief Financial Officer Gordon Naylor The new funds will be used to repay existing debt to fund CSL s capital management plan and for general corporate purposes

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927497719/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies - Response to News Reports on FDA Inspections
    has today made reference to FDA inspection reports issued to CSL Biotherapies at the completion of scheduled inspections of its influenza vaccine manufacturing site in April 2010 and March 2011 The FDA and the TGA conduct regular inspections of all manufacturers whose products they licence These inspections are a normal part of the regulatory process and ensure companies continuously improve their compliance with cGMP Inspection reports known as Form 483 s contain observations only and are not a final determination of a manufacturers compliance with cGMP The final determination of compliance is made after manufacturers have had the opportunity to respond to the observations and discuss them with the FDA The observations recorded during the inspection of CSL Biotherapies influenza vaccine operations in April 2010 were addressed to the satisfaction of the FDA within that same year Many of the observations from the March 2011 inspection have also been satisfactorily addressed Those requiring further attention were contained in the FDA Warning Letter issued to CSL Biotherapies in June 2011 This was covered extensively by the media at that time These remaining compliance issues are in the process of resolution and CSL Biotherapies is working closely with the FDA and the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927385518/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies - Restricted Supply of BenPen
    News Archive CSL Biotherapies Restricted Supply of BenPen CSL Biotherapies Restricted Supply of BenPen Melbourne Australia 27 09 2011 CSL Biotherapies has advised hospitals that BenPen Benzylpenicillin is on restricted supply in Australia and New Zealand until December 2011 This is due to the inability of our supplier to fulfil our orders on time BenPen is supplied by Austrian based Sandoz GMBH a division of Novartis Sandoz GMBH has advised CSL Biotherapies that it is currently unable to meet global demand for BenPen BenPen is a narrow spectrum intravenous penicillin used in the treatment of serious infections including wound infections sepsis and meningitis CSL Biotherapies recognises the significance of this shortage and is actively working with Sandoz GMBH to expedite supplies of BenPen into Australia as soon as possible said Dr Alan Paul Medical Director for CSL Biotherapies In addition to the rationing of current supplies CSL Biotherapies is asking hospitals to consider the use of alternative antibiotic agents where possible and appropriate We recognise that this is not optimal however it will ensure that limited supplies of BenPen are reserved for patients with the most urgent clinical need We understand that BenPen is an essential medicine and are committed

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927348167/prdetail.htm (2014-01-05)
    Open archived version from archive